Core Viewpoint - Peijia Medical-B (09996) is experiencing a stock price increase, with a rise of over 3% and a current price of 5.92 HKD, driven by the announcement of share purchases by CEO Dr. Zhang Yi [1] Group 1: Company Developments - Dr. Zhang Yi, the company's CEO and Chairman, will begin purchasing company shares on the open market starting December 1, 2025, with a total investment not exceeding 15 million HKD [1] - There is a possibility that Dr. Zhang may further increase his shareholding in the company in accordance with applicable laws and regulations [1] Group 2: Product and Market Performance - According to a report from CITIC Securities, the company's TAVR (Transcatheter Aortic Valve Replacement) products are experiencing continuous growth in volume and steadily increasing market share [1] - The GeminiOneTEER system, TaurusTrio aortic regurgitation valve, and TaurusNXT dry valve TAVR are expected to receive intensive approvals between the end of 2025 and 2026, which will drive accelerated growth in the valve business [1] - The MonarQ tricuspid valve system has initiated global clinical trials, and the company's cutting-edge technology business has secured external financing, indicating a clear path for innovation and international expansion [1]
港股异动 | 沛嘉医疗-B(09996)现涨超3% 董事长于公开市场增持股份 多款产品即将取得重要进展